" based on my assumption that Philips make the device and Biom the tests that go in the device, and these tests are composed of more than just the bonding agent so I can't see how ADO can simply take the place of Biom"
My answer to this would be :
How do they replace Biomerieux?
Anteo become a global assay developer for Philips
Maybe that has something to do with the Commercialisation Australia grant - Increasing jobs and exports?
Anteo have achieved in the first 3 months of having the device in their hands what Biomeriux and Future Diagnostics couldnt achieve over a 5 year plus timeframe.
I asked Geoff at the AGM how much he thought had already been spent with Future trying to get it to work and his guess was $25m
Now if ADO can achieve a better result than $25m worth of development in a 3 month period I would say the value of ANTEO and MIXNGO speaks for itself.
This is why the Mixngo technology is truly disruptive.
Combine that with tens of billions of healthcare sales that Mixngo can improve = $$
ADO Price at posting:
18.0¢ Sentiment: Buy Disclosure: Held
